polmacoxib polmacoxib polmacoxib (trade name acelex) is a nonsteroidal anti-inflammatory drug (nsaid) used to treat osteoarthritis. it was developed as cg100649 and approved for use in south korea in february 2015. it inhibits the enzymes carbonic anhydrase and cox-2. a study in healthy volunteers showed drug effects on urinary prostaglandin metabolites for both polmacoxib and celecoxib that suggest a similar cardiovascular risk profile. further work by this group developed dose-exposure relationships of polmacoxib to guide clinical development strategies. polmacoxibclinical datatrade namesacelexother namescg100649atc codem01ah07 (who) identifiers iupac name 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide cas number301692-76-2pubchem cid9841854chemspider8017569uniiij34d6ypaokeggd10656 ychemblchembl166863chemical and physical dataformulac18h16fno4smolar mass361.39 g·mol−13d model (jsmol)interactive image smiles cc1(c(=o)c(=c(o1)c2=cc=c(c=c2)s(=o)(=o)n)c3=cc(=cc=c3)f)c inchi inchi=1s/c18h16fno4s/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10h,1-2h3,(h2,20,22,23)key:ijwpafmifnsigd-uhfffaoysa-n